Vetoquinol has just launched its Marbocyl 10% online case study competition in which veterinary surgeons are being invited to provide information about how they treat E.coli mastitis. Two winners (one in the UK and one in Ireland) will win a BCF EASI-SCAN cattle ultrasound scanner with goggles worth over £6000.
Vetoquinol's large animal product manager, Susan Mitchell said: "We hope that this case study competition will help us gather further information on how E.coli mastitis is treated by veterinary surgeons in the UK and Ireland. I would encourage large animal veterinary surgeons to be part of this UK and Irish survey to highlight the severity of the disease and share their success stories."
The competition will run until the end of October 2011.
For your chance to win a BCF EASI-SCAN and goggles visit http://www.vetoquinol.co.uk/.
The kit contains the ergonomically designed Henke-Sass Wolf injector with an adjustable dose selector, five single piece Intranasal RSP nozzles – with ‘luer’ lock attachment, which supports easier removal, cleaning and/or replacement – and instructions for use.
For more information, contact your local MSD Animal Health account manager.
Defra has announced plans to form a new Animal Health and Welfare Board for England which will bring experts including farmers, veterinary surgeons, welfare experts and others from outside Government together with the Chief Veterinary Officer and civil servants to make direct policy recommendations on policy affecting the health and welfare of all kept animals such as farm animals, horses and pets.
According to Agriculture Minister Jim Paice, it is the first time that people affected by Government policy on animal health and welfare will make recommendations on those policies directly to Ministers.
Mr Paice said: "This is a completely new way of working. It replaces the old ways, where the people most affected by decisions were kept at arm's length from policy making on those subjects.
"This is about the Big Society not just existing in our communities, but in the heart of Government - helping to put the decisions in the hands of those who are doing the work on the ground.
"We've already seen the success of a partnership between farmers and the Government with the work that's been done on bluetongue - which has seen the disease virtually eradicated in this country."
Final decisions on animal health and welfare policy will remain in the hands of Government Ministers.
The Board will be made up of around 12 members, 5 senior Defra officials including the Chief Veterinary Officer, and 7-8 external members including the chair. The external members will have experience and knowledge of kept and farmed animals, animal and veterinary science, and animal welfare, and could be farmers, veterinarians, animal welfare experts.
The Board and its members will have to represent the views of all stakeholders so will be expected to communicate with them regularly.
The Board's responsibilities will include:
The Board will not be set up as a non departmental public body or arms length body. It will form part of the internal structure of Defra.
Commenting on the announcement, Harvey Locke, President of the British Veterinary Association, said: "The BVA is delighted that both the Advisory Group and Ministers have taken note of the veterinary profession's views in drawing up these plans.
"We said from the outset that genuine responsibility sharing has to be achieved before cost sharing can be discussed and we warned against earlier plans to separate animal health policy from animal welfare policy, as the two are intrinsically linked.
"Animal health and welfare policy issues require expert, scientific input and it will be essential that the new Board includes veterinary representation. We believe that the Board will provide the right mechanism for ensuring decisions are based on sound science.
"The new Board will also have to work closely with the three devolved administrations to ensure that animal health and welfare policies across the UK are joined up and complementary."
CEVA Animal Health is giving away a digital thermometer with every purchase of three bottles of Rehydion gel Formula Plus
According to CEVA, dehydration can be a big problem for farmers, causing weakness, scouring and weight loss but Rehydion gel Formula Plus has transformed the management of this common condition. Historically treatments could not be added to milk as the bicarbonate, citrate and the high levels of glucose in the solutions inhibited milk clotting. Rehydion gel Formula Plus, however, helps to maintain a low abomasal pH and guarantees milk clotting.
The company says calves with dehydration and diarrhoea still tend to crave milk, which not only provides vital fluid but is also the best possible source of energy for weight gain. Milk also has many other advantages such as helping with gut healing and providing natural antimicrobial actions. Rehydion gel Formula Plus's high palatability and efficient dilution in milk allows weight gain to continue, even in cases of severe scour.
CEVA also has a leaflet to help farmers minimise the problem of dehydration and diarrhoea in beef and dairy cattle. To order copies and for further information contact your CEVA representative or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Dechra says necrotic enteritis can be treated with a variety of therapeutic antibiotics but that the first choice antibiotics¹ for treatment are narrow spectrum antibiotics, like phenoxymethylpenicillin.
Phenocillin is an 800 mg/g powder for use in drinking water. It is lactose free, and Dechra says its high solubility makes it ideal for concentrated stock solutions and convenient for modern poultry farming. There is a zero withdrawal time so egg production is unaffected.
Dechra Brand Manager Emma Jennings said: “Necrotic enteritis is the most common bacterial disease in modern broiler flocks that can be financially devastating for farmers.
"The high concentration means easy dosage and handling with less waste and the lactose free formula reduces the risk of biofilm development resulting in a high quality and effective product, supporting the responsible use of antimicrobials.
"Phenocillin is a highly effective treatment and we anticipate it will become the preferred solution for veterinary professionals and end users to treat this disease that can very suddenly devastate broiler flocks."
For more information, visit: http://bit.ly/2nAboGU
The self-adhesive dressing, which uses a patented natural polymer, adapts to any part of the body and sets fast, acting as a waterproof barrier to the external environment which shields the site from unwanted moisture and bacterial ingress and allows the tissue underneath to repair in a protected environment.
It is proven to prevent the loss of therapeutic sprays when it is used as a barrier1.
The company says NoBACZ Bovine is easy to apply with a clean gloved hand and offers up to seven days’ protection without the need to reapply.
It is suitable for use on any site of the body, except the eyes, and has been especially widely used on hooves, horn buds and udders.
The liquid barrier dressing does not need to be removed as it will self-degrade and its ingredients dissolve naturally with no residue.
Dr Jonathan Powell, Director of Biomineral Research and Imaging at the University of Cambridge’s Department of Veterinary Medicine, and chief executive officer and co-founder of NoBACZ Healthcare, said: “Following several years of research at the University of Cambridge and comprehensive market analysis which identified an unmet need across the farming industry, we are absolutely delighted to launch NoBACZ Bovine, which offers unparalleled protection against harsh farm conditions, revolutionising wound protection in cattle and enhancing the health and welfare of the national herd.”
Mike Kerby, veterinary surgeon from Synergy Farm Health, who has used NoBACZ Bovine over many months, added: “I have been using NoBACZ Bovine for a while in cattle affected with UCD (udder cleft dermatitis) and DD (digital dermatitis) lesions as well as on wounds and granulomas.
"It is my clinical impression that it counters bacterial colonisation rapidly and promotes re-epithelialisation, which in turn helps to prevent the occurrence of proud flesh or reduces the mass of any existing granulomata.
"Application is simple and quick, with clients also finding it easy to reapply regularly within set treatment protocols.
"In addition to this, it was seen as a huge advantage that bandages and their removal are not involved, nor are antibiotics, making it labour saving, sustainable and eco-friendly.”
www.nobacz.com
Reference
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life and that the onset of immunity for BRSV is 6 days (for calves vaccinated from the day of birth onwards) and 5 days (for calves vaccinated from the age of one week onwards).
Onset of immunity for Pi3V is one week after vaccination. The duration of immunity is 12 weeks for both viruses.
From a practical standpoint, the new license means Bovilis Intranasal RSP Live can now be used on farm at the same time as other early life interventions associated with newborn calves – for example, colostrum/first milk feeding, navel management, tagging, jacketing and necessary pen movements.
Additionally, Bovilis Intranasal RSP Live can be used up to six hours after mixing with the solvent, which MSD says is the longest of all the available intranasal vaccines for these pathogens.
The vaccine is supplied as a nasal suspension product that doesn’t need a specific applicator – although for maximum flexibility an easy-clean injector and nozzle kit is available for vaccinating multiple animals.
The vaccine is available in 5x1 dose, 5 dose and 5x5 dose packs.
Till then, veterinary surgeons are advised to make due diligent attempts to source a UK-authorised product before considering importing an alternative medicine.
Procaine hydrochloride is used in farm animal medicine in particular, to provide local and regional anaesthesia for a range of procedures including calving, lambing, caesarean operations, castration and dehorning of cattle, with demand particularly high in the spring.
Simon Doherty, BVA President, said: "We’re pleased that VMD has issued some clarification to answer our concerns over procaine hydrochloride shortages. BVA had heard from some veterinary practices that they were only able to get hold of a fraction of what they needed, which would have resulted in a very acute impact on farm animal welfare. Although we had moved to get assurances sooner, we appreciate that there are formal routes for reporting and that the announcement of any shortage must be handled sensitively to avoid exacerbating the problem.
"VMD’s clarification is especially timely as this is a period of peak seasonal demand for these products. We will keep our members closely informed of any further developments."
The review, announced earlier this year, was recommended to RCVS Council by its Standards Committee following its exploration of the implications of new technologies for both animal health and welfare and veterinary regulation.
The main areas under consideration include the provision of 24-hour emergency cover and the interpretation and application of an animal being under the care of a veterinary surgeon.
The initial stages of this review had been drafted for Standards Committee to consider at its meeting on 9 September, where the outline timetable was also discussed.
Standards Committee Chair Melissa Donald, said: "This is set to become one of our most fundamental reviews of RCVS guidance in recent years.
"Considering the complexity of the issues in question, and their importance to animal owners and the professions alike, it is vital that we allow ourselves enough time to ensure this review is as thorough and comprehensive as possible.
"We have a clear responsibility to seek, understand and, where we can, accommodate the opinions and experiences of as many different people from within and around the professions and the public as possible. I would urge my fellow vets and vet nurses to please find some time to consider these issues very carefully over the coming weeks and months, and to send us their views."
The review will comprise several stages and is expected to take around 12 months to complete. The outline timetable, which may be subject to change, is as follows:
October 2019 – January 2020: six-week Call for Evidence, followed by independent qualitative analysis of all evidence received
February – March: Select Committee-style meetings and independent qualitative analysis of additional evidence gathered [NB this stage is subject to Standards Committee requirements, depending on the evidence gathered.]
April – June: Consider all evidence and draft any new policy
July – August: six-week public consultation on draft policy
September – October: independent review of consultation responses, and production of any proposals for change
November 2020: Finalise any proposals for change and publish any new guidance
To support and promote the various stages of the review the College is also planning a programme of stakeholder engagement, and will also provide regular updates on progress to both Council and the wider profession.
Members of the professions and the public will be able to follow the progress of the review via the RCVS website at: www.rcvs.org.uk/undercare
Zoetis has relaunched a broad spectrum intramammary treatment for clinical mastitis, as Lincocin Forte S.
For vets seeking to prescribe an alternative first-choice tube, independent mastitis authority Dr Andrew Bradley suggests it could be a logical, efficacious option, offering the combination of two active ingredients (lincomycin and neomycin) not available in other intramammary tubes.1
Zoetis points to studies which show that In combination, these have been found to have much higher efficacy than the sum of the two parts against Staphylococci aureus.2&3
The company says Lincocin Forte is effective against Gram positive and Gram negative pathogens, in particular staphylococcus, streptococcus and coliform bacteria.
In trials, the treatment produced clinical cure rates 21% higher than an ampicillin-cloxacillin comparison in undifferentiated mastitis cases. As first choice treatment for S uberis clinical mastitis, bacteriological cure rates were similar to a penicillin-streptomycin comparison.4 Against S aureus, aesculin-positive streptococci, and E coli, combined clinical-bacteriological cure rates were 175%, 32% and 21% higher respectively with Lincocin Forte S than ampicillin-cloxacillin treatment.
Zoetis vet Jude Roberts said these findings underpin the treatment's relaunch and its suitability as a first choice therapy for new clinical mastitis cases.
Lincocin Forte S is a water-based formulation, which Jude says helps achieve good distribution in the udder and can be easier to infuse that oil-based tubes, particularly into hardened quarters associated with E coli infections.
Dr Bradley adds that water-based formulation is likely to be less irritant to udder tissues than oil-based tubes, and may improve distribution. He also suggests that "not being a fluoroquinolone or 3rd/4th generation cephalosporin may also help vets fulfil their 'appropriate and justified' prescribing responsibilities."
The recommended treatment is one 10ml syringe per infected quarter at each of three consecutive milkings. Milk from treated cows can be sold for human consumption 84-hours after the last treatment.References:
Defra's new measures include:
Eleven additional licences for badger control covering parts of Devon, Wiltshire, Somerset, Dorset and Cheshire. Licences have been granted for supplementary badger control in areas of Gloucestershire and Somerset which have completed their original four-year licences.
The relaunch of the Badger Edge Vaccination Scheme following suspension due to a global shortage of TB vaccine, with groups invited to submit expressions of interest and feedback on the criteria for the scheme.
A new bTB Advisory Service for farmers to provide advice on-farm and by phone or email to farmers in High Risk and Edge Areas on bTB biosecurity and risk-based trading, set to launch this autumn.
Tighter control of Inconclusive Reactors (IRs) in the High Risk and Edge Area, to come into force from 1 November.
British Veterinary Association (BVA) President Gudrun Ravetz said: "Today’s announcement sees 11 new licences issued and, while BVA supports badger culling as part of a comprehensive strategy for tackling bovine TB, we will continue to call on the Government to use the targeted and humane method of cage trapping and shooting only - rather than the current method of controlled shooting.
"As one of the many tools in the toolbox, we welcome the re-commencement of the Badger Edge Vaccination Scheme, particularly if used as a ‘firebreak’ to mitigate the spread of the disease into the low risk areas. The introduction of a TB Advisory Service will provide valuable additional support for farmers, who we’d encourage to continue working with local vets on biosecurity and herd health planning.
"Yet we are concerned that Government policy seems to have moved away from the original, evidence-based proposal of a six-week time limit for badger control within the open season, which enables an intensive, coordinated and effective operation in order to secure optimum disease control benefits.
"In terms of numbers, it is clear that badger population estimates have previously demonstrated considerable uncertainty and imprecision. It is critical that as accurate as possible population estimates, using an evidence-based methodology, are obtained and made openly available.
"We would urge clarity over cull timeframes, numbers and mid-cull review methodology to ensure that the progress made, enabling the application for Officially TB Free status, is not undermined."
Today’s Defra update follows a consultation on licensed badger control conducted at the start of 2017, to which the British Veterinary Association (BVA), British Veterinary Zoological Society (BVZS) and the Association of Government Veterinarians (AGV) submitted a formal, joint response.
Photo: Young Eurasian Badger (Meles Meles), by BadgerHero, CC BY-SA 3.0
DG Sanco, the EU Directorate General for Health and Consumers, has launched a worldwide photo competition to mark World Vet Year: 'Vets in your daily life'
Entries need to be photos of a vet (or vets) at work or in any situation which shows the diverse nature of the job. Five winners will win 1000 Euros worth of photographic equipment. The overall winner will win an additional 2000 Euros worth of photographic equipment. All winners will also be given travel and accommodation for the awards ceremonies in Paris and Brussels.
Anyone (except for employees of the European Institutions, and their families) can enter the competition, which closes on 31st March 2011. More details can be found at: www.vetsinyourdailylife.org.
Here's the promotional video for the competition:
Newmarket-based Test and Treat was one of three finalists, for its U-Treat test which enables vets to diagnose a UTI and get antibiotic sensitivity results in an hour.
Rachel Kirkby MRCVS, Business Development Director at Test and Treat, said: "It’s a great accolade to be recognised by such a prestigious award. The Vet Record Innovation Award celebrates new innovations that can bring about improvement and make a real difference to vets in practice – and that’s exactly what we’re aiming to do with U-Treat.”
The second finalist was the Animal Welfare Assessment Grid, developed by Public Health England (PHE), in collaboration with the University of Surrey School of Veterinary Medicine. Initially developed in zoos, rescue and research centres, there are plans now to develop it for use in small animal practice and in the farm sector.
The overall winner was PBD Biotech for Actiphage, its test for bTB and Johne's disease which gives very early detection, thereby allowing vets and farmers to prevent the spread of infection.
For more information, visit: https://bvajournals.onlinelibrary.wiley.com/doi/10.1002/vetr.267
Bimeda has announced the launch of Bilovet, a new tylosin-based antibiotic for cattle and pigs.Padraig Hyland, Head of Technical Veterinary Services at Bimeda said: ''It is with great pleasure that I announce the launch of our much anticipated Bilovet 200 mg/ml solution for injection for cattle and pigs as the latest addition to Bimeda's range of essential antibiotics.
Bilovet contains Tylosin 200 mg/ml and is the second Tylosin-based injectable antibiotic to be licensed for cattle - including dairy cattle - in the UK. Bilovet is licensed in cattle for the treatment of respiratory infections, metritis, mastitis, interdigital necrobacillosis and calf diphtheria as well as a range of pig infections, including enzootic pneumonia, haemorrhagic enteritis, erysipelas, arthritis and metritis".
Bimeda's Head of Bimeda R+D, Xavier Molins said: "Bilovet is a completely new development for a product that includes a new species (cattle). Bimeda have made a significant investment in bringing Bilovet to market, including conducting new Environmental Risk Assessment studies according to current guidelines and regulations.''
For more information, ring 01248 725 400 or email: uksales@bimeda.com
Scientists at the University of Liverpool have, for the first time, revealed that digital dermatitis (DD) has been present on hoof knifes used on cattle and sheep following research1 jointly funded by DairyCo and EBLEX.
The research conducted at the University investigated if DD Treponeme can be present on equipment used to trim cattle and sheep hooves. The research team, led by Dr Nicholas Evans and Professor Stuart Carter of the University of Liverpool and in collaboration with Roger Blowey MRCVS, tested trimming equipment used on cattle and sheep with digital dermatitis and after it was disinfected.
After trimming, DD was present on 97% of cattle blades and 100% of sheep blades. This was reduced to 29% and 46% respectively after disinfection.
Dr Evans said: "It has long been considered that digital dermatitis was spread in slurry which we have some evidence for and are continuing to investigate but now, for the first time, we have discovered the digital dermatitis bugs in the farm environment.
"However, the high detection rate of digital dermatitis bacteria on trimming blades soon after trimming cattle and sheep hooves from digital dermatitis cases suggests this may be a significant and worrying route for the transmission of this infectious condition."
Leigh Sullivan, who conducted the field work as part of her study, said: "Interestingly, in the world of human dentistry, a completely different species of the bacteria is found to cause gum disease. Furthermore, studies have shown it will adhere to metal on orthodontic braces which is consistent with our detection of the digital dermatitis Treponeme on metallic trimming knives."
Dr Jenny Gibbons, DairyCo research & development manager, added: "This DairyCo and EBLEX-funded study could help farmers, vets and hoof trimmers to understand more about the transmission of digital dermatitis between cows and farms. A logical precaution to limit the spread is to disinfect hoof trimming equipment between animals and between farms."
To find out more about this and other R&D projects, DairyCo is hosting a research day on 17 July at Trenault Farm, Launceston, Cornwall.
To book a place, visit: dairyco.org.uk/researchday2014
Fourth year veterinary students from the University of Sydney's Faculty of Veterinary Science have produced a nude calendar in which they use a variety of strategically placed animals to protect their modesty.
The calendar, called Under the Overalls, features a variety of animals, including three lucky (depending on your point of view) llamas, a calf, three sheep and a rather unfortunate fish.
It's all in aid of charity. For more information, visit https://www.facebook.com/undertheoveralls, or you can buy the calendar for $20 at www.undertheoveralls.com.
Picture: House of Cameo
Protek Biochem Ltd., a company set up by champion horse-rider Debbie Topping, has won the rights to sell Envirocair Veterinary, a new range of disinfectants and sanitisers targeted at dogs, cats and other domestic pets, as well as horses and farm animals.
The product is claimed to kill 99.99% of all viral, bacterial and fungal infections, and lasts for 14 days.
Debbie said: "I did not consider myself a businesswoman, just a normal horse-rider and animal lover. However, I was so impressed when I tried Envirocair Veterinary that, when I was offered the opportunity to become the main UK distributor, I jumped at the chance."
According to the company, the product is being used by a number of the horses and trainers heading to the London Olympics in 2012. It is now being rolled out across the rest of the UK's animal care sector.
Debbie says that veterinary surgeons, farmers, dog kennels, animal rescue centres, breeders and others will all be able to benefit from the new product: "Envirocair Veterinary doesn't harm skin or irritate the respiratory tract, so you don't need to get dressed up in special clothing every time you use it.
"Used properly, it quite literally kills the threat of major animal diseases such as parvovirus in dogs, which can otherwise be fatal in less than 72 hours.
"It's not an exaggeration to say that Envirocair will protect the health and even save the lives of countless numbers of animals across the UK."
Debbie signed the distribution agreement with the manufacturer Biotech International Ltd last month, before officially launching Envirocair Veterinary this week.
For more information on Protek Biochem Ltd or Envirocair Veterinary, visit http://www.protekbiochem.com/.
Bayer Animal Health has announced the launch of, Dinalgen (ketoprofen), an NSAID injection approved for use in cattle, pigs and horses.
Dinalgen is available as a 150mg/ml Solution for Injection, and Bayer says the more concentrated format allows the product to provide the smallest dose, fast relief NSAID currently available for cattle in the UK.
In cattle, Dinalgen is licensed for the reduction of inflammation and pain associated with lameness, post-partum, and musculoskeletal disorders; the reduction of fever associated with bovine respiratory disease; and the reduction of inflammation, fever and pain in acute clinical mastitis in combination with antimicrobial therapy where appropriate. The withdrawal period for milk is zero hours and for meat two days.
In pigs, Dinalgen is licensed for the reduction of pyrexia in cases of respiratory disease and postpartum dysgalactia syndrome in sows, in combination with antimicrobial therapy.
In horses, Dinalgen is licensed for the reduction of inflammation and pain associated with osteoarticular and musculoskeletal disorders, including lameness, laminitis, osteoarthritis, synovitis, and tendinitis. It also aids the reduction of visceral pain associated with colic.
Sharon Cooksey, MRCVS, FAP group product manager at Bayer, said: “We are excited to have this new addition to our portfolio. It is a good fit with our existing products.
"A recent field study*, carried out by Nottingham university, has shown that NSAID (ketoprofen) treatment maximises the chance of recovery from lameness in dairy cattle. Lameness remains one of the “big three” issues in dairy practice so maybe it is time we moved on from hoof blocks and/ or trimming in isolation and onto a more multi-layer approach. We have some great support tools in the pipeline to help both vets and farmers recognise and manage animals at risk for lameness.”
For further product information visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
In the study, which was supported by MSD and led by Rosie Lyle of Bishopton Veterinary Group, 18 farmers placed temperature loggers in the fridge where they normally store vaccines. Temperatures were then monitored between February and April. Throughout this period, 89% of loggers recorded a temperature outside the 2–8°C range at least once, and 43% recorded temperatures outside this range more than 50% of the time.
The authors say that these findings raise potential concerns about vaccine efficacy.
Rosie found that 55% of the loggers recorded a temperature over 8°C, and 39% recorded a temperature below 2°C.
Across all the fridges monitored, the maximum temperature recorded was 12°C and the minimum was -11.5°C.
Rosie said: "This is a surprisingly wide range. Obviously, these findings are concerning for farmers as we know that both too high and too low temperatures can impair vaccine efficacy.
"Live vaccines tend to be particularly sensitive to elevated temperatures, whereas inactivated vaccines are more affected by freezing, especially when the adjuvant contains aluminium salts".
"It’s important for both farmers and vets to be aware of potential concerns about vaccine efficacy, given the possible impact on herd health and the potential for vaccine failure to reduce trust in vaccines and herd health recommendations".
In light of Rosie’s findings, other XLVets practices are now encouraging farmers to take action to improve medicine storage, including using max/min thermometers or temperature loggers to track fridge temperature, as well as taking steps to maximise the efficiency of each fridge.
Susan Goodfellow, Marketing Manager at XLVets, said: "We wouldn’t have known that this is an important issue to highlight to farmers without collecting the information, so Rosie’s study was very valuable.
"In the XLVets community, we support clinical leadership with these kind of projects – we actively collect data and make sure that farmers can benefit from the latest findings. As a group of independent practices working together, we can achieve much more than we could in isolation."
The materials available include a scour management guide for farmers and a more detailed version for vets. They encourage a focus on three main areas for improved, sustained disease control: maximising calf immunity; identifying any causal agents and how to effectively manage an outbreak of calf scour on farm.
MSD Animal Health veterinary adviser Dr Kat Baxter-Smith (pictured right) said: "Even with good disease prevention protocols in place, calf scour outbreaks can still occur. But when they do, remedial action should focus on these three key areas to resolve the outbreak as quickly as possible and reduce the chances of another costly event happening in the future.
The company highlights a 202 survey of more than 300 farms, which found that over 80% of UK calf rearing units had seen a case of scour in the previous 12 months; with 50% of farms admitting to experiencing calf deaths due to the disease1. Costs are estimated at £57.94 per case but this does not include the longer-term impacts of the disease on future calf productivity.2,3
References
Tom graduated from the Royal Veterinary College (RVC) in 2017 and joined Synergy Farm Health full-time in 2018, after completing his postgraduate diploma (PGDipVCP) with the RVC.
Nominated by his practice, Tom is described as a fine example of a dedicated caring professional who is passionate about sustainability, has a keen sense of his clients’ needs, and has developed strong working relationships with the farms under his care.
The judging panel found that Tom uses data effectively in herd health planning to highlight areas of improvement, working in partnership with his clients to promote disease prevention and profitability.
Tom’s clients spoke of his knowledge and caring attitude and how much he is valued as part of their team.
Tom said: “It was a privilege to be a part of the awards and to see farmers and businesses acknowledged - farmers don’t always get the recognition they deserve and seeing British dairying showcased was amazing.
"I hope winning is reward for the time and effort colleagues at Synergy put into young vets too, and that I can put it to good use supporting clients and working with other organisations within the dairy industry.
"My aim as a vet has been simply to support clients the best I could, both clinically and emotionally, so to have won made it a fantastic night and one I won’t be forgetting!”
The runner up as Charlie Mays of LLM Vets, who the judging panel praised for making effective changes on farm towards preventive healthcare and using data to assist with health and profitability.
Charlie also lobbies government to support the interests of the farmer and the industry.
Sabrina Jordan from Virbac said: ‘Virbac has been supporting dairy vets with products and services for over 50 years and recognise the commitment of young dairy vets to the profession.
"The standard of nominations into this category was outstanding, and our winner and highly commended nominees are a true credit to the veterinary profession, both are shining lights of the future’.
Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.
The RCVS issued a reminder today that there is just over a month left before the 1 April deadline for all veterinary practice premises from which medicines are to be supplied to be registered with the College.
Just over 4,500 premises have applied for registration since November 2008. This includes about 750 premises not previously listed with the College, demonstrating the usefulness of the process, which will enable the government to fulfil its obligations under European law to maintain and improve traceability of, and accountability for, veterinary medicines.
From 1 April it will be an offence for a veterinary surgeon to supply a veterinary medicinal product from any practice premises not registered with the RCVS. On conviction, those committing the offence may be liable to prosecution, which may include a fine or prison sentence. Veterinary surgeons convicted of criminal offences are also considered by the College's Preliminary Investigation Committee to decide whether the conviction would affect the individual's fitness to practise and should be referred to the Disciplinary Committee.
In addition to ensuring their practice premises are registered, veterinary surgeons also need to keep a record of other places where medicines are stored, so these can be considered during an inspection - such as vets' homes or cars, or perhaps a charity premises from which veterinary work is carried out and where medicines are stored. Such records will not be published, although some of those premises may need to be registered in their own right.
Practices accredited under the RCVS Practice Standards Scheme will be inspected by the RCVS; non-compliance with medicines standards will be dealt with under the rules of the Scheme. The Veterinary Medicines Directorate (VMD) will carry out inspections of other registered premises to ensure compliance with the Veterinary Medicines Regulations. Where non-compliance is noted, the VMD will take a proportionate enforcement approach ranging from issuing advice to, where appropriate, serving an improvement notice or seizing medicines.